Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Recommendation of “Hold” from Analysts

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have been given an average recommendation of “Hold” by the seventeen research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, fourteen have given a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $8.87.

A number of brokerages have recently issued reports on SAGE. Wall Street Zen lowered shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 7th. Bank of America began coverage on shares of Sage Therapeutics in a research note on Tuesday, March 11th. They issued an “underperform” rating and a $5.00 target price on the stock. Finally, Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a research note on Friday, April 25th.

Sage Therapeutics Price Performance

Shares of SAGE stock opened at $6.70 on Wednesday. The firm has a market capitalization of $419.56 million, a P/E ratio of -1.02 and a beta of 0.18. The company’s fifty day moving average price is $6.97 and its two-hundred day moving average price is $6.87. Sage Therapeutics has a 12 month low of $4.62 and a 12 month high of $13.47.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.02). The company had revenue of $14.06 million during the quarter, compared to analyst estimates of $14.12 million. Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. The business’s revenue for the quarter was up 78.0% compared to the same quarter last year. During the same quarter last year, the company posted ($1.80) EPS. On average, sell-side analysts anticipate that Sage Therapeutics will post -3.52 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. AlphaQuest LLC bought a new position in Sage Therapeutics in the 1st quarter worth about $32,000. Picton Mahoney Asset Management boosted its holdings in shares of Sage Therapeutics by 126.0% in the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 3,581 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Sage Therapeutics in the first quarter valued at approximately $37,000. KLP Kapitalforvaltning AS bought a new position in shares of Sage Therapeutics in the fourth quarter valued at approximately $49,000. Finally, Ieq Capital LLC bought a new position in shares of Sage Therapeutics in the fourth quarter valued at approximately $57,000. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.